hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06332469, orgStudyIdInfo id: INSERT feasibility, briefTitle: Evaluation of an Internet Based Education and Support Program for Patients Awaiting Kidney Transplantation, acronym: INSERT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Linkoeping University, class: OTHER_GOV, descriptionModule briefSummary: The goal of this study is to test the feasibility study of an internet based education and support program for patients awaiting kidney transplantation. The study is designed as a national pilot randomized controlled trial with a waitlist control group, to test the feasibility, acceptability, and potential effects of the intervention on patients' physical and mental health., conditionsModule conditions: Chronic Kidney Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The intervention group gets immediate access to the 9 week program, and the waitlist control group gets access after a 9 week waiting period., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Internet based education and support program for patients awaiting kidney transplantation, outcomesModule primaryOutcomes measure: Kidney transplant understanding tool (K-TUT), primaryOutcomes measure: Self-care in chronic illness inventory v.4c, primaryOutcomes measure: The Self-Efficacy for Managing Chronic Disease 6-item Scale (SES6G, primaryOutcomes measure: Pearlin Mastery Scale, primaryOutcomes measure: The Depression Anxiety Stress Scales 21 (DASS-21), primaryOutcomes measure: Acceptance of chronic health conditions scale (ACHC), primaryOutcomes measure: EQ-5D-5L, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06332456, orgStudyIdInfo id: ICM 2023-3169, briefTitle: Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography, acronym: RESIST, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Matthieu Pelletier-Galarneau, MD MSc, class: OTHER, descriptionModule briefSummary: The aim of this study is to demonstrate that positron emission tomography imaging with Rubidium-82 (radioactive tracer) can non-invasively detect and quantify changes in renal blood flow (renal perfusion) and renal vascular resistance in both healthy subjects and patients with renal insufficiency. Ultimately, the results of this study will contribute to a better understanding of the role of positron emission imaging in the evaluation of patients with renal diseases., conditionsModule conditions: Renal Microcirculation With Rubidium Positron Emission Tomography, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Renal blood flow in units of mL/min/100g, secondaryOutcomes measure: Renal vascular resistance in units of mmHg/mL/min/100g, secondaryOutcomes measure: Correlation between renal vascular resistance measured with PET and measured with echography, secondaryOutcomes measure: Coefficient of repeatability of renal blood flow, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Montreal Heart Institute, status: RECRUITING, city: Montréal, state: Quebec, zip: H1T 1C8, country: Canada, contacts name: Matthieu Pelletier-Galarneau, role: CONTACT, phone: 5143763330, phoneExt: 4418, email: matthieu.pelletier-galarneau@icm-mhi.org, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06332430, orgStudyIdInfo id: CW-202, briefTitle: Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2026-05-30, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Canwell Biotech Limited, class: INDUSTRY, descriptionModule briefSummary: A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas., conditionsModule conditions: Solid Tumor, conditions: Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 27, type: ESTIMATED, armsInterventionsModule interventions name: CAN2109, outcomesModule primaryOutcomes measure: Safety and tolerability, primaryOutcomes measure: Recommended Phase 2 Dose (RP2D), secondaryOutcomes measure: To determine the efficacy of CAN2109, secondaryOutcomes measure: To evaluate the pharmacodynamics of CAN2109, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, city: Guangzhou, state: Guangdong, zip: 510535, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06332417, orgStudyIdInfo id: REC/RCR&AHS/23/0364, briefTitle: Combined Effects of Ba-Duan-Jin Based Deep Breathing Exercises and Forced Expiratory Technique, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2024-06-05, completionDateStruct date: 2024-06-15, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: This study will be a randomized control trial. A total of 68 patients will be recruited and randomly assign to the experimental group or the control group in a 1:1 ratio. Participants in the experimental group will receive a 8-week Ba-duan jin exercise training intervention along with Forced Expiratory Technique at least 3 days a week and 30 minutes a day, while participants in the control group will be only given Forced Expiratory intervention and will be told to maintain their original lifestyle for 8 weeks along with standard COPD treatment., conditionsModule conditions: Chronic Obstructive Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Ba-Duan-Jin Based Deep Breathing Exercises, interventions name: FET (Forced Expiratory Technique), outcomesModule primaryOutcomes measure: 36-Item Short Form Survey (SF-36), primaryOutcomes measure: FEV1/FVC ratio, primaryOutcomes measure: Exercise Tolerance : 6 minute walk test, primaryOutcomes measure: Forced vital capacity (FVC), primaryOutcomes measure: Forced expiratory volume (FEV1), eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Social Security Teaching Hospital, status: RECRUITING, city: Lahore, state: Punhab, zip: 42000, country: Pakistan, contacts name: Faisal Rehman, MBBS, role: CONTACT, phone: +924299230227, email: info@pessi.punjab.gov.pk, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06332404, orgStudyIdInfo id: B3002024000047, briefTitle: Hypoglossal Nerve Stimulation Therapy in Patients With Obstructive Sleep Apnea: Belgian Registry, acronym: B-HNS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2034-04, completionDateStruct date: 2034-04, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: University Hospital, Antwerp, class: OTHER, descriptionModule briefSummary: Hypoglossal nerve stimulation (HNS) therapy (Inspire system) is intended for the treatment of patients with moderate to severe obstructive sleep apnea (OSA) who cannot be effectively treated with the first-line treatment options. Recently, the request for reimbursement of the Inspire system in Belgium was approved.The aim is to create a registry of OSA patients that are treated with HNS (Inspire system) within routine clinical care at the Antwerp University Hospital., conditionsModule conditions: Obstructive Sleep Apnea, conditions: Sleep Apnea, conditions: Apnea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 225, type: ESTIMATED, armsInterventionsModule interventions name: Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA), outcomesModule primaryOutcomes measure: Delta apnea-hypopnea index (AHI) as measured by a polysomnography, secondaryOutcomes measure: % of patients that reach treatment success defined by a 50% reduction in AHI and an on therapy AHI of < 20 events/h OR an on therapy AHI of < 15 events/h, secondaryOutcomes measure: Therapy adherence defined by the amount of hours therapy usage per night., secondaryOutcomes measure: Delta oxygen desaturation index (ODI) as measured by a polysomnography, secondaryOutcomes measure: Daytime sleepiness measured by the Epworth Sleepiness Scale (ESS) questionnaire, secondaryOutcomes measure: Disease-specific quality of life as measured by the Functional Outcomes of Sleep Questionnaire-30 (FOSQ-30) questionnaire, secondaryOutcomes measure: Degree of snoring measured by the Visual Analogue Scale (VAS) questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Antwerp University Hospital, city: Edegem, state: Antwerp, zip: 2650, country: Belgium, contacts name: Dorine Van Loo, Msc, role: CONTACT, phone: +3238215780, email: dorine.vanloo@uza.be, contacts name: Olivier Vanderveken, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.15662, lon: 4.44504, hasResults: False
protocolSection identificationModule nctId: NCT06332365, orgStudyIdInfo id: ID: 3938/2022, briefTitle: Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers, acronym: salivaLichen, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-03, primaryCompletionDateStruct date: 2023-12-15, completionDateStruct date: 2024-02-19, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Pia Lopez Jornet, class: OTHER, descriptionModule briefSummary: Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus, conditionsModule conditions: Oral Lichen Planus, conditions: Oral Lichen Planus Related Stress, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Randomization: The enrolled subjects were randomly assigned to one of two treatment protocols using a computer-generated table. This method ensures impartial allocation and avoids biases in treatment selection for each patient.Masking: Medications were prepared and packaged in identical, sealed, and numbered envelopes by the hospital pharmacy and a clinician not involved in the subsequent phases of the study. Each sealed envelope contained the protocol assignment for individual patients and written instructions for the application of the medications. Moreover, clinicians involved in treatment evaluation at each follow-up session were blinded to the treatment assigned to each patient., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Acetonide triamcinolone 0.2% +hyaluronicacid 1%, interventions name: Corticoid Acetonide triamcinolone 0.2%, interventions name: Hyaluronic acid 1%, outcomesModule primaryOutcomes measure: Pain assessment scale, secondaryOutcomes measure: OHIP-14 questionnaire, secondaryOutcomes measure: reduction of clinical signs measure, secondaryOutcomes measure: Salivary level of oxidative stress biomarker, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pia Lopez Jornet, city: Murcia, zip: 30004, country: Spain, geoPoint lat: 37.98704, lon: -1.13004, hasResults: False
protocolSection identificationModule nctId: NCT06332352, orgStudyIdInfo id: 00173470, briefTitle: Intra-articular Platelet-Rich Plasma for Acetabular Labral Tears, acronym: PRP for ALT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2025-01-25, completionDateStruct date: 2026-01-25, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: University of Utah, class: OTHER, descriptionModule briefSummary: Platelets are small cells found in the blood that help form clots and stop bleeding. Platelet-rich plasma is blood that contains more platelets than normal and can be given to help people with pain. Tears of the Labrum to the hip (the cartilage "suction cup" that holds the ball to the socket of the hip) cause hip pain. The study wants to see if a portion of the patient's blood, the platelets, will help relieve hip pain and function.Participation requires completing surveys by email, text message, in person, and/or by telephone. Medical tests will also be done to track the health of participants., conditionsModule conditions: Acetabular Labrum Tear, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: PRP, outcomesModule primaryOutcomes measure: Pain & Function Improvements, secondaryOutcomes measure: Visual Analog Scale (VAS), secondaryOutcomes measure: Harris Hip Scores (HHS), secondaryOutcomes measure: International Hip Outcome Tool (iHOT-12), secondaryOutcomes measure: EQ-5D (EuroQual 5D), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Utah - Department of Orthopaedics, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84108, country: United States, contacts name: Luke A Johnson, BS, role: CONTACT, phone: 801-213-3379, email: luke.a.johnson@utah.edu, contacts name: Daniel Cushman, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Derek Stokes, MD, role: SUB_INVESTIGATOR, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06332326, orgStudyIdInfo id: E-10840098-772.02-4966, briefTitle: Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-23, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Medipol University, class: OTHER, descriptionModule briefSummary: The purpose of this study: To investigate the effectiveness of non-invasive vagus nerve stimulation and vestibular rehabilitation applications in patients diagnosed with Unilateral Vestibular Hypofunction (UVH)., conditionsModule conditions: Vestibular Diseases, conditions: Vestibular Vertigo, conditions: Vertigo, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 40 patients diagnosed with UHV were included. Patients were randomized into 2 separate groups (20 people in the vestibular rehabilitation group, 20 people in the vagus nerve stimulation group in addition to vestibular rehabilitation)., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: non-invasive vagus nerve stimulation, interventions name: vestibular rehabilitation, outcomesModule primaryOutcomes measure: Modified-CTSIB, primaryOutcomes measure: Semitandem test, primaryOutcomes measure: tandem test, primaryOutcomes measure: one-leg standing test, primaryOutcomes measure: Unterberger test, primaryOutcomes measure: VAS Visual Analogue Scale (dizziness severity), primaryOutcomes measure: Dynamic visual acuity test, secondaryOutcomes measure: Dizziness Handicap Inventory Scale, secondaryOutcomes measure: Tampa Kinesiophobia Scale, secondaryOutcomes measure: Hospital Anxiety and Depression Scale (HAD), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Istanbul Medipol University, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: tuğba türk kalkan, MD, role: CONTACT, phone: +905334956459, email: tugbatrkk@gmail.com, contacts name: tugba türk kalkan, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06332300, orgStudyIdInfo id: ADBL-LC-003, briefTitle: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Jiangsu Province Nanjing Brain Hospital, class: OTHER, descriptionModule briefSummary: This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Adebelimumab+Famitinib + FOLFIRI+Ariely, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: iPFS, secondaryOutcomes measure: iDoR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shengcun Fang, status: RECRUITING, city: Nanjing, state: Jiangsu, country: China, contacts name: Shengcun Fang, PhD, role: CONTACT, phone: +86 13404163638, email: Fang1984@aliyun.com, contacts name: Jian Zhang, Master, role: CONTACT, phone: +86 13095457871, email: 919939410@qq.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06332287, orgStudyIdInfo id: 2023-NSCLC, briefTitle: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-03-27, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Jiangsu Province Nanjing Brain Hospital, class: OTHER, descriptionModule briefSummary: To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasis。, conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Trilaciclib, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: combination of Trilaciclib and Pemetrexed, outcomesModule primaryOutcomes measure: Duration of severe neutropenia (DSN), secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, secondaryOutcomes measure: Incidence of grade 3 and 4 hematologic toxicity, secondaryOutcomes measure: Incidence of G-CSF treatment, secondaryOutcomes measure: Incidence of platelet transfusion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fang Shencun, status: RECRUITING, city: Suzhou, state: Jiangsu, zip: 210029, country: China, contacts name: fang S cun, M.D., role: CONTACT, phone: 83728558, phoneExt: 025, email: fang1984@aliyun.com, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False